1. Home
  2. LOCO vs CLLS Comparison

LOCO vs CLLS Comparison

Compare LOCO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$16.78

Market Cap

411.3M

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.35

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCO
CLLS
Founded
1980
1999
Country
United States
France
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.3M
394.4M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
LOCO
CLLS
Price
$16.78
$3.35
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$14.17
$8.33
AVG Volume (30 Days)
320.2K
36.3K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
4.65
N/A
EPS
0.27
N/A
Revenue
$401,701,000.00
N/A
Revenue This Year
$3.60
N/A
Revenue Next Year
$3.98
$0.98
P/E Ratio
$61.78
N/A
Revenue Growth
5.68
N/A
52 Week Low
$8.99
$1.62
52 Week High
$17.40
$5.48

Technical Indicators

Market Signals
Indicator
LOCO
CLLS
Relative Strength Index (RSI) 64.33 55.42
Support Level $13.52 $2.86
Resistance Level N/A $3.41
Average True Range (ATR) 0.50 0.16
MACD 0.09 0.05
Stochastic Oscillator 66.36 86.96

Price Performance

Historical Comparison
LOCO
CLLS

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: